{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:33:20Z","timestamp":1792168400763,"version":"4.4.0"},"reference-count":44,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1486,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1468-1293.2011.00941.x","type":"journal-article","created":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T04:01:20Z","timestamp":1312776080000},"page":"620-631","source":"Crossref","is-referenced-by-count":33,"title":["Randomized comparison of metabolic and renal effects of saquinavir\/r or atazanavir\/r plus tenofovir\/emtricitabine in treatment-na\u00efve HIV-1-infected patients"],"prefix":"10.1111","volume":"12","author":[{"given":"SME","family":"Vrouenraets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FWNM","family":"Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Fernandez Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GJ","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AG","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DT","family":"Jayaweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Slama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WD","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"DeJesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"van Eeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the BASIC study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,7]]},"reference":[{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-Moller","year":"2003","journal-title":"AIDS"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/QAD.0b013e328339192f","article-title":"Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population","volume":"24","author":"Lang","year":"2010","journal-title":"AIDS"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB4|cit4","first-page":"2603","article-title":"Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects","volume":"17","author":"Murphy","year":"2003","journal-title":"48-week results"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB6|cit6","first-page":"92","article-title":"Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients","volume":"3","author":"Cahn","year":"2004","journal-title":"results from two randomized clinical trials"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00126334-200406010-00005","article-title":"Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir","volume":"36","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00042560-199908150-00011","article-title":"Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy","volume":"21","author":"Moyle","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB9|cit9","first-page":"1056","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy","volume":"189","author":"Fontas","year":"2004","journal-title":"are different antiretroviral drugs associated with different lipid profiles?"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB10|cit10","first-page":"785","article-title":"Pharmacokinetic study of saquinavir hard gel caps\/ritonavir in HIV-1-infected patients","volume":"54","author":"Autar","year":"2004","journal-title":"1600\/100\u2003mg once-daily compared with 2000\/100\u2003mg once-daily and 1000\/100\u2003mg twice-daily"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/135965350801300302","article-title":"Long-term efficacy and safety of first-line therapy with once-daily saquinavir\/ritonavir","volume":"13","author":"Ananworanich","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB12|cit12","first-page":"36","article-title":"Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule\/ritonavir in antiretroviral-naive, HIV-infected patients","volume":"8","author":"Montaner","year":"2006","journal-title":"MedGenMed"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e31815ace6a","article-title":"Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients","volume":"47","author":"Malan","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1468-1293.2005.00328.x","article-title":"The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations","volume":"6","author":"Shafran","year":"2005","journal-title":"HIV Med"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/QAI.0b013e3181c190f4","article-title":"Insulin sensitivity in multiple pathways is differently affected during zidovudine\/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy","volume":"53","author":"van Vonderen","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/QAI.0b013e318189a780","article-title":"Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study","volume":"49","author":"Tien","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB17|cit17","first-page":"1813","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity","volume":"20","author":"Noor","year":"2006","journal-title":"demonstrable differences in vitro and clinically"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","article-title":"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients","volume":"42","author":"Jemsek","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB19|cit19","unstructured":"Jackson A Patel N Lo G Gazzard B Moyle G. Program and abstract of the 14th Conference on Retroviruses and Opportunistic Infections"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB21|cit21","first-page":"1781","article-title":"A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"ACTG 5206"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB22|cit22","first-page":"3","article-title":"Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection","volume":"12","author":"Moyle","year":"2010","journal-title":"AIDS Rev"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/QAD.0b013e32832ba904","article-title":"Effects of switching from lopinavir\/ritonavir to atazanavir\/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients","volume":"23","author":"Stanley","year":"2009","journal-title":"AIDS"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir","volume":"43","author":"Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfg349","article-title":"A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate","volume":"18","author":"Hoek","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB31|cit31","first-page":"1228","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients","volume":"170","author":"Lang","year":"2010","journal-title":"a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB32|cit32","unstructured":"Durand M Sheehy O Baril J-G Lelorier J Tremblay C Center GR. Program and abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB33|cit33","unstructured":""},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0b013e328315a7a5","article-title":"Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults","volume":"22","author":"Carr","year":"2008","journal-title":"AIDS"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB35|cit35","unstructured":"Moyle G Hu W Yang R et al Programs and abstracts of the 12th European AIDS Conference"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0166-3542(00)00102-9","article-title":"HIV protease inhibitors block adipogenesis and increase lipolysis in vitro","volume":"47","author":"Lenhard","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/135965350501000202","article-title":"Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors","volume":"10","author":"Jones","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/QAD.0b013e3283021a4f","article-title":"Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes","volume":"22","author":"Jones","year":"2008","journal-title":"AIDS"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350701200407","article-title":"Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages","volume":"12","author":"Lagathu","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3851\/IMP1533","article-title":"HIV protease inhibitors activate the adipocyte renin angiotensin system","volume":"15","author":"Boccara","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study","volume":"12","author":"Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB42|cit42","first-page":"646","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients","volume":"372","author":"Molina","year":"2008","journal-title":"48 week efficacy and safety results of the CASTLE study"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB43|cit43","first-page":"761","article-title":"Estimating glomerular filtration rate in HIV-infected adults in Africa","volume":"13","author":"Stohr","year":"2008","journal-title":"comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae"},{"key":"10.1111\/j.1468-1293.2011.00941.x-BIB44|cit44","first-page":"367","article-title":"Gemini","volume":"50","author":"Walmsley","year":"2009","journal-title":"a noninferiority study of saquinavir\/ritonavir versus lopinavir\/ritonavir as initial HIV-1 therapy in adults"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2011.00941.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1468-1293.2011.00941.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T18:17:41Z","timestamp":1712686661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2011.00941.x"}},"subtitle":["Metabolic and renal effects of SQV\/r vs. ATV\/r"],"short-title":[],"issued":{"date-parts":[[2011,8,7]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2011.00941.x","relation":{},"ISSN":["1464-2662"],"issn-type":[{"value":"1464-2662","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,7]]}}}